INFLAMAPLS
Inflamalps is a biopharmaceutical company established in Valais, Switzerland. Their mission is ‘’to discover and develop novel medicines to treat inflammation with a focus on chronic inflammatory diseases of the eye and of the skin” Their team comprises experienced pharmaceutical industry and biotechnology company managers with significant track record in drug development, management and financing. Their focus is on developing topical treatments for inflammation-mediated diseases in ophthalmology and dermatology.
INFLAMAPLS
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2012-01-01
Address:
Monthey, Valais, Switzerland
Country:
Switzerland
Website Url:
http://www.inflamalps.com
Total Employee:
1+
Status:
Active
Total Funding:
1.8 M CHF
Technology used in webpage:
SPF SSL By Default LetsEncrypt Apache IPv6 ReCAPTCHA ReCAPTCHA V2 Infomaniak Network Infomaniak Mail
Similar Organizations
Immutep
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Current Advisors List
Board_member
Board_member
Current Employees Featured
Eduard Vidovic Chief Medical Officer @ Inflamapls
Chief Medical Officer
Andrea Cesura Chief Scientific Officer @ Inflamapls
Chief Scientific Officer
Philippe Meuwly Co-Founder @ Inflamapls
Co-Founder
Charles Woler Co-Founder @ Inflamapls
Co-Founder
Founder
Official Site Inspections
http://www.inflamalps.com
- Host name: h2web260.infomaniak.ch
- IP address: 84.16.76.207
- Location: Switzerland
- Latitude: 47.1449
- Longitude: 8.1551
- Timezone: Europe/Zurich
More informations about "Inflamapls"
Inflamalps SA
Inflamalps is developing INF101 for the treatment of dry eye in ophthalmology. Since 2020, Inflamalps is leading a drug discovery effort to discover novel anti-microbial molecules in …See details»
Inflamalps SA - Board of Directors
Board of Directors. Dr. Vincent Mutel, Chairman, CEO and co-founder was co-founder, CEO and vice chairman of the board of Addex Pharmaceuticals Ltd, a well-established public Swiss …See details»
Inflamapls - Crunchbase Company Profile & Funding
Inflamalps is a biopharmaceutical company established in Valais, Switzerland. Their mission is ‘’to discover and develop novel medicines to treat inflammation with a focus on chronic …See details»
Inflamalps SA - Contacts
Contact Details. Inflamalps SA Route de l'Ile-au-Bois 1A 1870 Monthey, Switzerland; © INFLAMALPSSee details»
INFLAMALPS SA Company Profile - Dun & Bradstreet
Inflamalps sa. d&b business directory home / business directory / professional, scientific, and technical services / scientific research and development services / switzerland / valais / …See details»
Inflamalps SA - Swiss Biotech
Inflamalps is a biopharmaceutical company established in Valais, Switzerland. Our mission is ‘’to discover and develop novel medicines to treat inflammation with a focus on chronic …See details»
Inflamalps SA - VentureRadar
Inflamalps is a biopharmaceutical company established in Valais, Switzerland. Our mission is ‘’to discover and develop novel medicines to treat inflammation with a focus on chronic …See details»
Inflamalps SA - BioAlps
Avenue de Sécheron 15 1202 Geneva, Switzerland T +41 22 545 12 91. c/o BIOPÔLE SA Secteur Esplanade / Bâtiment Serine Route de la Corniche 8 1066 Epalinges, SwitzerlandSee details»
Inflamalps - Products, Competitors, Financials, Employees, …
Inflamalps is a biopharmaceutical company focused on the discovery of anti-inflammatory and anti-microbial molecules. The company is developing treatments for conditions such as dry …See details»
Inflamalps SA: Drug pipelines, Patents, Clinical trials - Synapse
Jun 17, 2023 Explore Inflamalps SA with its drug pipeline, therapeutic area, technology platform, , Technology Platform:Unknown, Drug:INF-101.See details»
Inflamalps Company Profile 2024: Valuation, Investors ... - PitchBook
Inflamalps General Information Description. Operator of a biopharmaceutical company intended to progress in the treatment of chronic inflammatory diseases. The company engages in …See details»
Inflamalps SA - Executive Management
Executive Management. Dr. Vincent Mutel, Chairman, CEO and co-founder was co-founder, CEO and vice chairman of the board of Addex Pharmaceuticals Ltd, a well-established public Swiss …See details»
Inflamalps SA - Monthey, Switzerland - bionity.com
Inflamalps is a biopharmaceutical company established in Valais, Switzerland Our mission is ‘’to discover and develop novel medicines to treat inflammation with a focus on chronic …See details»
Inflamapls - Funding, Financials, Valuation & Investors - Crunchbase
Inflamalps is a biopharmaceutical company established in Valais, Switzerland. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. ...See details»
Inflamalps takes part in a significant biopharmaceutical research ...
Nov 16, 2021 With the Innosuisse project, Inflamalps wants to reach the next level. The objective is to split the available extracts in order to isolate the antibiotic molecules and to …See details»
INF 101 - AdisInsight
Inflamalps is developing INF 101 (earlier OX 1001), a nitric oxide (NO)-hybridised protease inhibitor, for the topical treatment of dry eyes. INF 101 was INF 101 Next ... If your …See details»
Inflamalps SA - INF101
INF101 is a new molecule in-preclinical development for the topical treatment of dry eye, an ophthalmological indication with a market potential above CHF 2 billion.. INF101 was shown to …See details»
Inflamalps SA - News & Events
December 2021, Inflamalps announces that Innosuisse, the Swiss fund for Innovation granted CHF650’000 to a consortium led by Inflamalps and comprising the University of Turin in Italy, …See details»
Research programme: TNFR1 blockers - Inflamalps - AdisInsight
Sep 28, 2020 Inflamalps was developing type 1 tumour necrosis factor receptor (TNFR1) blockers for the topical treatment of dermatological disorders. Active molecules from Research …See details»
Inflamalps SA - Therapeutic Focus
Anti-microbial drug discovery: In 2020, Inflamalps actively engaged in the discovery and development of novel molecules for the treatment of multi resistant microbe infections. We …See details»